Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

C4 Therapeutics Inc

CCCC
Current price
6.72 USD -0.08 USD (-1.18%)
Last closed 6.91 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 470 600 832 USD
Yield for 12 month +105.50 %
1Y
3Y
5Y
10Y
15Y
CCCC
21.11.2021 - 28.11.2021

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

18.5 USD

P/E ratio

Dividend Yield

Current Year

+20 756 000 USD

Last Year

+31 096 000 USD

Current Quarter

+3 261 000 USD

Last Quarter

+11 072 000 USD

Current Year

+13 019 000 USD

Last Year

+23 524 000 USD

Current Quarter

+1 570 000 USD

Last Quarter

+9 077 000 USD

Key Figures CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -137 151 008 USD
Operating Margin TTM -1147.72 %
PE Ratio
Return On Assets TTM -21.53 %
PEG Ratio
Return On Equity TTM -49.5 %
Wall Street Target Price 18.5 USD
Revenue TTM 20 756 000 USD
Book Value 4.07 USD
Revenue Per Share TTM 0.42 USD
Dividend Share
Quarterly Revenue Growth YOY 14.3 %
Dividend Yield
Gross Profit TTM -86 745 000 USD
Earnings Share -2.67 USD
Diluted Eps TTM -2.67 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CCCC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CCCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 15.6883
Price Sales TTM 24.4908
Enterprise Value EBITDA -2.5447
Price Book MRQ 2.0654

Financials CCCC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CCCC

For 52 weeks

1.06 USD 11.88 USD
50 Day MA 8.35 USD
Shares Short Prior Month 5 287 035
200 Day MA 4.47 USD
Short Ratio 3.24
Shares Short 9 149 358
Short Percent 18.92 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics